Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Bit Digital Inc (BTBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Bit Digital Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Bit Digital Inc trades at $1.33 (market cap $453.60M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 20.7× Bit Digital Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| BIO | BTBT | |
|---|---|---|
Market Cap | $9.39B | $453.60M |
Sector | Health | Technology |
52-Week High | $356.25 | $4.22 |
52-Week Low | $241.71 | $1.23 |
Enterprise Value | $9.14B | $742.91M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
BTBT trades at $1.38 with a 1.1% daily gain, showing modest momentum despite a bearish technical signal from moving averages. The company reported revenue of $113.56M in 2025 but posted a significant net loss of $80.32M, with profitability metrics like ROE at -38.98% indicating financial strain. Analyst coverage remains limited but unanimously positive, with 2 buy ratings and no hold or sell recommendations. Recent news highlights upcoming Q2 2026 earnings and mixed price target discussions.
The outlook for BTBT is clouded by persistent losses and negative cash flow from operations, though financing activities provide liquidity. Investment opportunities hinge on a potential earnings turnaround, while risks include sustained unprofitability, competitive pressures, and reliance on external funding. The stock's low valuation multiples may attract value seekers, but caution is warranted given the fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
